Peripheral Vascular Devices Market by Product (Balloon Inflation Devices, Catheters, Grafts), Technology Type (Minimally Invasive Surgeries, Open Surgery), Material Type, Indication, Patient Types, End-User - Global Forecast 2025-2032
Description
The Peripheral Vascular Devices Market was valued at USD 14.66 billion in 2024 and is projected to grow to USD 15.50 billion in 2025, with a CAGR of 6.19%, reaching USD 23.72 billion by 2032.
A clear and authoritative introduction framing modern peripheral vascular device dynamics across clinical practice, technology, and commercial strategy
Peripheral vascular devices occupy a pivotal role in contemporary cardiovascular care, driving improvements in patient outcomes while reshaping procedural standards across a spectrum of indications. This executive summary synthesizes current technological trajectories, regulatory pressures, clinical adoption patterns, and commercial dynamics to provide an integrated view for decision-makers. The analysis grounds itself in a cross-sectional understanding of device categories, procedural modalities, material science, patient demographics, and care settings, offering practical intelligence to inform investment, R&D, and market access strategies.
As care pathways evolve toward minimally invasive approaches and value-based reimbursement, stakeholders must reconcile clinical efficacy with cost and operational constraints. This introduction frames the subsequent sections by outlining the major forces influencing product development and procurement, including innovation in stent and graft technologies, the increasing prominence of catheter-based interventions, and the interplay between device material choices and long-term durability. It also highlights how end-user diversity - from ambulatory surgical centers to high-acuity hospitals - shapes adoption timelines and commercial approaches.
Finally, this opening contextualizes the deeper dives that follow, clarifying the analytical lens used and the intended audience: executives and clinical leaders seeking evidence-based guidance to prioritize portfolio decisions, navigate regulatory and tariff-related complexity, and accelerate patient-centric innovation across global markets.
Pervasive clinical and technological shifts are accelerating minimally invasive adoption, materials innovation, and integrated device-imaging solutions across care pathways
The landscape of peripheral vascular care is experiencing transformative shifts driven by technological maturation, procedural migration, and evolving clinical guidelines. Minimally invasive techniques have consolidated their position as first-line interventions for many occlusive and functional vascular conditions, prompting device makers to prioritize low-profile delivery systems, improved radial force characteristics, and polymer or nitinol alloys that balance flexibility with fatigue resistance. Concurrently, there is a discernible movement toward integrated systems that pair stents and plaque modification devices with advanced imaging and navigation platforms to optimize lesion preparation and deployment accuracy.
Regulatory and reimbursement environments are adapting in parallel, with an emphasis on real-world evidence and post-market surveillance to demonstrate long-term safety and cost-effectiveness. This has created pressure for manufacturers to invest in robust clinical registries and to design trials that capture meaningful patient-centric endpoints. Additionally, industry players are responding to acute clinical needs by innovating graft materials and vascular closure technologies that reduce procedural time and complication rates, thereby enabling broader adoption in outpatient settings. These shifts are accelerating collaborations across medtech, imaging, and digital health domains, reshaping how devices are designed, positioned, and supported in clinical practice.
Anticipated tariff adjustments in 2025 will force supply chain realignments, localized manufacturing decisions, and portfolio prioritization to safeguard market access
Tariff policy changes slated for 2025 present a complex set of operational and strategic considerations for manufacturers, distributors, and clinical providers engaged in peripheral vascular care. Increased import duties on specific device categories could elevate landed costs for capital-intensive products and consumables, prompting supply chain reconfiguration and a reassessment of manufacturing footprints. Some firms may respond by shifting production closer to key markets, renegotiating supplier contracts, or adjusting pricing strategies to preserve channel relationships and maintain procurement momentum among hospitals and ambulatory centers.
Beyond direct cost impacts, tariff-driven shifts are likely to influence product portfolios and innovation roadmaps. Firms may prioritize modular designs and regional sourcing of critical components to mitigate exposure, while others might accelerate partnerships with local contract manufacturers to retain market access. On the provider side, procurement committees could favor devices with established supply continuity and predictable total cost of ownership rather than newer entrants with uncertain logistics. Importantly, tariff dynamics are likely to be uneven across product types; high-volume, lower-margin consumables such as catheters may be more sensitive to incremental duty changes than specialized capital devices, which can absorb cost variation through service agreements and bundled pricing models.
Comprehensive segmentation insights reveal product, technology, material, indication, patient type, and end-user distinctions that drive differentiated market strategies
A nuanced segmentation view reveals multiple vectors for competitive differentiation and targeted commercialization. By product, the market encompasses a broad spectrum from balloon inflation devices and guidewires to vascular closure devices, with core categories including catheters, grafts, stents, and plaque modification systems. Within catheters, distinctions among long peripheral intravenous catheters, midline catheters, and short peripheral intravenous catheters determine design priorities related to dwell time, flexibility, and infection control. Grafts vary materially and functionally across biological grafts, ePTFE grafts, and polyester grafts, each offering discrete trade-offs in patency, handling, and host response. Stent technologies bifurcate into balloon-expandable and self-expanding designs, where radial strength, foreshortening behavior, and delivery profile drive clinical selection.
Technology type further stratifies opportunity, with minimally invasive surgeries - notably angioplasty and stenting - increasingly dominating intervention rates relative to open procedures such as bypass surgery and endarterectomy, shaping demand for low-profile systems and adjunctive plaque modification devices. Material type segmentation highlights metal devices, including cobalt chromium, nitinol, and stainless steel alloys, contrasted against non-metal polymer and silicone constructs, each influencing device performance, imaging compatibility, and regulatory pathways. Indication-based segmentation differentiates functional peripheral vascular disease presentations like chronic venous insufficiency, Raynaud's disease, and varicose veins from occlusive conditions such as atherosclerosis, carotid artery disease, deep vein thrombosis, and lymphedema, thereby informing clinical trial endpoints and reimbursement narratives. Patient-type segmentation separates adult and geriatric populations, where acute and chronic conditions predominate, from pediatric cohorts facing acquired or congenital conditions, shaping device sizing, durability expectations, and regulatory evidence requirements. Finally, end-user segmentation across ambulatory surgical centers, clinics, and hospitals informs distribution strategies, service models, and sales engagement protocols, as each setting carries distinct procedural volumes, staffing competencies, and capital budgeting processes.
Regional market dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal distinct adoption drivers, regulatory nuances, and supply chain priorities
Regional dynamics in peripheral vascular device adoption reflect divergent clinical priorities, reimbursement frameworks, and industrial capabilities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established procedural volumes and consolidated payer systems support rapid uptake of advanced stent and closure technologies, while strong clinical research networks facilitate evidence generation and iterative product improvements. The regulatory environment is characterized by rigorous premarket evaluation complemented by extensive post-market registries that reinforce practitioner confidence in new platforms.
In Europe, Middle East & Africa, heterogeneous reimbursement pathways and varying hospital procurement models create differentiated corridors of adoption; some markets favor cost-effective, durable solutions, whereas others prioritize cutting-edge minimally invasive options supported by regional centers of excellence. Supply chain resiliency and localized manufacturing partnerships are particularly salient in this region. Asia-Pacific exhibits dynamic growth driven by demographic shifts, rising incidence of vascular disease, and increasing investment in healthcare infrastructure. Local manufacturers are expanding capabilities, and market entrants are adapting product designs and pricing to meet diverse clinical settings from tertiary hospitals to outpatient clinics. Across all regions, cross-border collaborations, harmonization of clinical evidence standards, and targeted market access programs will be essential to scale adoption and optimize patient outcomes.
Competitive and innovation landscape analysis highlights strategies incumbents and challengers use to capture clinical adoption and expand global footprints
Competitive dynamics in the peripheral vascular device space are shaped by a mix of large global medtech companies, specialized innovators, and nimble regional manufacturers. Leading players differentiate through multi-channel portfolios that pair interventional platforms with procedural accessories, bundled service offerings, and broad clinical evidence programs. Strategic priorities among incumbents include expanding device pipelines, investing in next-generation materials and delivery mechanisms, and deepening relationships with key opinion leaders to reinforce clinical adoption.
Emerging firms tend to focus on narrow technology bets such as novel plaque modification approaches, bioresorbable scaffolds, or next-generation closure devices, often leveraging venture capital and strategic partnerships to accelerate clinical validation. Mergers and acquisitions remain a common route to scale technology platforms, acquire regulatory approvals, and access established distribution networks. Across the competitive spectrum, successful companies are those that integrate regulatory strategy early, align product development with real-world clinician workflows, and support customers with training, procedural support, and robust service models that reduce total cost of care while improving outcomes.
Actionable strategic recommendations focused on resilient supply chains, evidence generation, clinician enablement, and targeted innovation to secure competitive advantage
Industry leaders should adopt a pragmatic, multi-dimensional playbook that balances near-term commercial resilience with long-term innovation. First, prioritize modular product architectures and standardized component sourcing to reduce tariff exposure and facilitate rapid scale across regions with variable trade policy. Simultaneously, invest in clinical registry programs and pragmatic trials that demonstrate meaningful patient-centered outcomes, enabling stronger reimbursement narratives and smoother regional adoption.
Second, deepen collaboration with procedural stakeholders by offering comprehensive training and proctoring services that shorten learning curves and increase procedure throughput. This should be paired with flexible commercial models, including bundled purchasing and outcome-linked pricing, to address budget constraints among ambulatory surgical centers and hospitals. Third, accelerate material science and delivery system innovation to target specific unmet needs: enhancing graft biocompatibility for long-term patency, refining stent radial mechanics for complex lesions, and optimizing catheter designs to reduce complications. Finally, pursue selective manufacturing localization and strategic supplier partnerships to safeguard supply continuity and cost predictability, while evaluating bolt-on acquisitions or licensing deals that fill portfolio gaps and speed market entry in priority geographies.
A transparent and multi-method research approach integrating secondary evidence, clinician interviews, technical validation, and scenario analysis to underpin recommendations
The research methodology underpinning this analysis combined rigorous secondary research, targeted primary interviews, and systematic data validation to ensure robust and actionable insights. Secondary sources included peer-reviewed clinical literature, regulatory filings, device approvals, and publicly available procurement documentation to map historical trends and establish baseline technical characteristics. Complementing this, primary research encompassed structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and device engineers to capture first-hand perspectives on clinical needs, adoption barriers, and performance expectations. These interviews were conducted across major geographies to ensure regional relevance and to surface nuanced differences in practice patterns.
Findings were triangulated by cross-referencing qualitative insights with device technical specifications, patent filings, and regulatory summaries to validate claims about material choices, design trade-offs, and procedural workflows. Where appropriate, scenario analysis was applied to assess the operational implications of tariff shifts and regulatory changes. Limitations include variability in publicly reported clinical outcomes and the inherent lag between emerging clinical practice and published evidence. To mitigate these constraints, the methodology emphasized corroboration across multiple independent sources and prioritized high-confidence inputs for strategic recommendations.
A concise conclusion tying together technological trends, segmentation insights, tariff implications, and strategic priorities to guide decisive action
In sum, the peripheral vascular devices ecosystem is at an inflection point where materials science, procedural innovation, and commercial strategy intersect to redefine patient care pathways. Minimally invasive approaches continue to expand their clinical remit, prompting manufacturers to innovate across stents, grafts, catheters, and closure systems while aligning evidence generation with payer expectations. Tariff dynamics and regional heterogeneity introduce operational complexity that necessitates adaptive supply chain strategies and localized market approaches.
Organizations that succeed will be those that pair technical excellence with pragmatic commercialization: investing in durable materials and delivery systems, funding robust real-world evidence programs, and engaging clinicians through hands-on training and value-based contracting. By synthesizing segmentation insights, regional nuances, and competitive dynamics, this executive summary offers a coherent framework for leaders to prioritize initiatives that drive clinical impact and sustainable growth. Moving from insight to implementation requires decisive actions in R&D prioritization, supply chain resilience, and market access planning to fully capture the evolving opportunities in peripheral vascular care.
Note: PDF & Excel + Online Access - 1 Year
A clear and authoritative introduction framing modern peripheral vascular device dynamics across clinical practice, technology, and commercial strategy
Peripheral vascular devices occupy a pivotal role in contemporary cardiovascular care, driving improvements in patient outcomes while reshaping procedural standards across a spectrum of indications. This executive summary synthesizes current technological trajectories, regulatory pressures, clinical adoption patterns, and commercial dynamics to provide an integrated view for decision-makers. The analysis grounds itself in a cross-sectional understanding of device categories, procedural modalities, material science, patient demographics, and care settings, offering practical intelligence to inform investment, R&D, and market access strategies.
As care pathways evolve toward minimally invasive approaches and value-based reimbursement, stakeholders must reconcile clinical efficacy with cost and operational constraints. This introduction frames the subsequent sections by outlining the major forces influencing product development and procurement, including innovation in stent and graft technologies, the increasing prominence of catheter-based interventions, and the interplay between device material choices and long-term durability. It also highlights how end-user diversity - from ambulatory surgical centers to high-acuity hospitals - shapes adoption timelines and commercial approaches.
Finally, this opening contextualizes the deeper dives that follow, clarifying the analytical lens used and the intended audience: executives and clinical leaders seeking evidence-based guidance to prioritize portfolio decisions, navigate regulatory and tariff-related complexity, and accelerate patient-centric innovation across global markets.
Pervasive clinical and technological shifts are accelerating minimally invasive adoption, materials innovation, and integrated device-imaging solutions across care pathways
The landscape of peripheral vascular care is experiencing transformative shifts driven by technological maturation, procedural migration, and evolving clinical guidelines. Minimally invasive techniques have consolidated their position as first-line interventions for many occlusive and functional vascular conditions, prompting device makers to prioritize low-profile delivery systems, improved radial force characteristics, and polymer or nitinol alloys that balance flexibility with fatigue resistance. Concurrently, there is a discernible movement toward integrated systems that pair stents and plaque modification devices with advanced imaging and navigation platforms to optimize lesion preparation and deployment accuracy.
Regulatory and reimbursement environments are adapting in parallel, with an emphasis on real-world evidence and post-market surveillance to demonstrate long-term safety and cost-effectiveness. This has created pressure for manufacturers to invest in robust clinical registries and to design trials that capture meaningful patient-centric endpoints. Additionally, industry players are responding to acute clinical needs by innovating graft materials and vascular closure technologies that reduce procedural time and complication rates, thereby enabling broader adoption in outpatient settings. These shifts are accelerating collaborations across medtech, imaging, and digital health domains, reshaping how devices are designed, positioned, and supported in clinical practice.
Anticipated tariff adjustments in 2025 will force supply chain realignments, localized manufacturing decisions, and portfolio prioritization to safeguard market access
Tariff policy changes slated for 2025 present a complex set of operational and strategic considerations for manufacturers, distributors, and clinical providers engaged in peripheral vascular care. Increased import duties on specific device categories could elevate landed costs for capital-intensive products and consumables, prompting supply chain reconfiguration and a reassessment of manufacturing footprints. Some firms may respond by shifting production closer to key markets, renegotiating supplier contracts, or adjusting pricing strategies to preserve channel relationships and maintain procurement momentum among hospitals and ambulatory centers.
Beyond direct cost impacts, tariff-driven shifts are likely to influence product portfolios and innovation roadmaps. Firms may prioritize modular designs and regional sourcing of critical components to mitigate exposure, while others might accelerate partnerships with local contract manufacturers to retain market access. On the provider side, procurement committees could favor devices with established supply continuity and predictable total cost of ownership rather than newer entrants with uncertain logistics. Importantly, tariff dynamics are likely to be uneven across product types; high-volume, lower-margin consumables such as catheters may be more sensitive to incremental duty changes than specialized capital devices, which can absorb cost variation through service agreements and bundled pricing models.
Comprehensive segmentation insights reveal product, technology, material, indication, patient type, and end-user distinctions that drive differentiated market strategies
A nuanced segmentation view reveals multiple vectors for competitive differentiation and targeted commercialization. By product, the market encompasses a broad spectrum from balloon inflation devices and guidewires to vascular closure devices, with core categories including catheters, grafts, stents, and plaque modification systems. Within catheters, distinctions among long peripheral intravenous catheters, midline catheters, and short peripheral intravenous catheters determine design priorities related to dwell time, flexibility, and infection control. Grafts vary materially and functionally across biological grafts, ePTFE grafts, and polyester grafts, each offering discrete trade-offs in patency, handling, and host response. Stent technologies bifurcate into balloon-expandable and self-expanding designs, where radial strength, foreshortening behavior, and delivery profile drive clinical selection.
Technology type further stratifies opportunity, with minimally invasive surgeries - notably angioplasty and stenting - increasingly dominating intervention rates relative to open procedures such as bypass surgery and endarterectomy, shaping demand for low-profile systems and adjunctive plaque modification devices. Material type segmentation highlights metal devices, including cobalt chromium, nitinol, and stainless steel alloys, contrasted against non-metal polymer and silicone constructs, each influencing device performance, imaging compatibility, and regulatory pathways. Indication-based segmentation differentiates functional peripheral vascular disease presentations like chronic venous insufficiency, Raynaud's disease, and varicose veins from occlusive conditions such as atherosclerosis, carotid artery disease, deep vein thrombosis, and lymphedema, thereby informing clinical trial endpoints and reimbursement narratives. Patient-type segmentation separates adult and geriatric populations, where acute and chronic conditions predominate, from pediatric cohorts facing acquired or congenital conditions, shaping device sizing, durability expectations, and regulatory evidence requirements. Finally, end-user segmentation across ambulatory surgical centers, clinics, and hospitals informs distribution strategies, service models, and sales engagement protocols, as each setting carries distinct procedural volumes, staffing competencies, and capital budgeting processes.
Regional market dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal distinct adoption drivers, regulatory nuances, and supply chain priorities
Regional dynamics in peripheral vascular device adoption reflect divergent clinical priorities, reimbursement frameworks, and industrial capabilities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established procedural volumes and consolidated payer systems support rapid uptake of advanced stent and closure technologies, while strong clinical research networks facilitate evidence generation and iterative product improvements. The regulatory environment is characterized by rigorous premarket evaluation complemented by extensive post-market registries that reinforce practitioner confidence in new platforms.
In Europe, Middle East & Africa, heterogeneous reimbursement pathways and varying hospital procurement models create differentiated corridors of adoption; some markets favor cost-effective, durable solutions, whereas others prioritize cutting-edge minimally invasive options supported by regional centers of excellence. Supply chain resiliency and localized manufacturing partnerships are particularly salient in this region. Asia-Pacific exhibits dynamic growth driven by demographic shifts, rising incidence of vascular disease, and increasing investment in healthcare infrastructure. Local manufacturers are expanding capabilities, and market entrants are adapting product designs and pricing to meet diverse clinical settings from tertiary hospitals to outpatient clinics. Across all regions, cross-border collaborations, harmonization of clinical evidence standards, and targeted market access programs will be essential to scale adoption and optimize patient outcomes.
Competitive and innovation landscape analysis highlights strategies incumbents and challengers use to capture clinical adoption and expand global footprints
Competitive dynamics in the peripheral vascular device space are shaped by a mix of large global medtech companies, specialized innovators, and nimble regional manufacturers. Leading players differentiate through multi-channel portfolios that pair interventional platforms with procedural accessories, bundled service offerings, and broad clinical evidence programs. Strategic priorities among incumbents include expanding device pipelines, investing in next-generation materials and delivery mechanisms, and deepening relationships with key opinion leaders to reinforce clinical adoption.
Emerging firms tend to focus on narrow technology bets such as novel plaque modification approaches, bioresorbable scaffolds, or next-generation closure devices, often leveraging venture capital and strategic partnerships to accelerate clinical validation. Mergers and acquisitions remain a common route to scale technology platforms, acquire regulatory approvals, and access established distribution networks. Across the competitive spectrum, successful companies are those that integrate regulatory strategy early, align product development with real-world clinician workflows, and support customers with training, procedural support, and robust service models that reduce total cost of care while improving outcomes.
Actionable strategic recommendations focused on resilient supply chains, evidence generation, clinician enablement, and targeted innovation to secure competitive advantage
Industry leaders should adopt a pragmatic, multi-dimensional playbook that balances near-term commercial resilience with long-term innovation. First, prioritize modular product architectures and standardized component sourcing to reduce tariff exposure and facilitate rapid scale across regions with variable trade policy. Simultaneously, invest in clinical registry programs and pragmatic trials that demonstrate meaningful patient-centered outcomes, enabling stronger reimbursement narratives and smoother regional adoption.
Second, deepen collaboration with procedural stakeholders by offering comprehensive training and proctoring services that shorten learning curves and increase procedure throughput. This should be paired with flexible commercial models, including bundled purchasing and outcome-linked pricing, to address budget constraints among ambulatory surgical centers and hospitals. Third, accelerate material science and delivery system innovation to target specific unmet needs: enhancing graft biocompatibility for long-term patency, refining stent radial mechanics for complex lesions, and optimizing catheter designs to reduce complications. Finally, pursue selective manufacturing localization and strategic supplier partnerships to safeguard supply continuity and cost predictability, while evaluating bolt-on acquisitions or licensing deals that fill portfolio gaps and speed market entry in priority geographies.
A transparent and multi-method research approach integrating secondary evidence, clinician interviews, technical validation, and scenario analysis to underpin recommendations
The research methodology underpinning this analysis combined rigorous secondary research, targeted primary interviews, and systematic data validation to ensure robust and actionable insights. Secondary sources included peer-reviewed clinical literature, regulatory filings, device approvals, and publicly available procurement documentation to map historical trends and establish baseline technical characteristics. Complementing this, primary research encompassed structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and device engineers to capture first-hand perspectives on clinical needs, adoption barriers, and performance expectations. These interviews were conducted across major geographies to ensure regional relevance and to surface nuanced differences in practice patterns.
Findings were triangulated by cross-referencing qualitative insights with device technical specifications, patent filings, and regulatory summaries to validate claims about material choices, design trade-offs, and procedural workflows. Where appropriate, scenario analysis was applied to assess the operational implications of tariff shifts and regulatory changes. Limitations include variability in publicly reported clinical outcomes and the inherent lag between emerging clinical practice and published evidence. To mitigate these constraints, the methodology emphasized corroboration across multiple independent sources and prioritized high-confidence inputs for strategic recommendations.
A concise conclusion tying together technological trends, segmentation insights, tariff implications, and strategic priorities to guide decisive action
In sum, the peripheral vascular devices ecosystem is at an inflection point where materials science, procedural innovation, and commercial strategy intersect to redefine patient care pathways. Minimally invasive approaches continue to expand their clinical remit, prompting manufacturers to innovate across stents, grafts, catheters, and closure systems while aligning evidence generation with payer expectations. Tariff dynamics and regional heterogeneity introduce operational complexity that necessitates adaptive supply chain strategies and localized market approaches.
Organizations that succeed will be those that pair technical excellence with pragmatic commercialization: investing in durable materials and delivery systems, funding robust real-world evidence programs, and engaging clinicians through hands-on training and value-based contracting. By synthesizing segmentation insights, regional nuances, and competitive dynamics, this executive summary offers a coherent framework for leaders to prioritize initiatives that drive clinical impact and sustainable growth. Moving from insight to implementation requires decisive actions in R&D prioritization, supply chain resilience, and market access planning to fully capture the evolving opportunities in peripheral vascular care.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
184 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Increasing adoption of drug-coated balloons to reduce restenosis in peripheral artery disease
- 5.2. Integration of artificial intelligence in imaging systems to enhance peripheral vascular intervention planning
- 5.3. Rising use of bioresorbable scaffolds to minimize long-term complications in peripheral vessels
- 5.4. Advancements in microcatheter technology to improve navigation through complex peripheral vasculature
- 5.5. Growing demand for portable vascular ultrasound devices for point-of-care lower limb assessments
- 5.6. Innovations in atherectomy devices for precise removal of peripheral arterial plaque
- 5.7. Expansion of telehealth remote monitoring solutions for post-procedural peripheral vascular patients
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Peripheral Vascular Devices Market, by Product
- 8.1. Balloon Inflation Devices
- 8.2. Catheters
- 8.2.1. Long Peripheral Intravenous Catheters
- 8.2.2. Midline Catheters
- 8.2.3. Short Peripheral Intravenous Catheter
- 8.3. Grafts
- 8.3.1. Biological Grafts
- 8.3.2. ePTFE Grafts
- 8.3.3. Polyester Grafts
- 8.4. Guidewires
- 8.5. Inferior Vena Cava Filters
- 8.6. Introducers
- 8.7. Plaque Modification Devices
- 8.8. Stents
- 8.8.1. Balloon-Expandable Stents
- 8.8.2. Self-Expanding Stents
- 8.9. Vascular Closure Devices
- 9. Peripheral Vascular Devices Market, by Technology Type
- 9.1. Minimally Invasive Surgeries
- 9.1.1. Angioplasty
- 9.1.2. Stenting
- 9.2. Open Surgery
- 9.2.1. Bypass Surgery
- 9.2.2. Endarterectomy
- 10. Peripheral Vascular Devices Market, by Material Type
- 10.1. Metal Devices
- 10.1.1. Cobalt Chromium
- 10.1.2. Nitinol
- 10.1.3. Stainless Steel
- 10.2. Non-Metal Devices
- 10.2.1. Polymer
- 10.2.2. Silicone
- 11. Peripheral Vascular Devices Market, by Indication
- 11.1. Functional Peripheral Vascular Disease
- 11.1.1. Chronic Venous Insufficiency
- 11.1.2. Raynaud's Disease
- 11.1.3. Varicose Veins
- 11.2. Occlusive Peripheral Vascular Disease
- 11.2.1. Atherosclerosis
- 11.2.2. Buerger’s Disease
- 11.2.3. Carotid Artery Disease
- 11.2.4. Deep Vein Thrombosis
- 11.2.5. Lymphedema
- 12. Peripheral Vascular Devices Market, by Patient Types
- 12.1. Adult & Geriatric
- 12.1.1. Acute Conditions
- 12.1.2. Chronic Conditions
- 12.2. Pediatric
- 12.2.1. Acquired Conditions
- 12.2.2. Congenital Conditions
- 13. Peripheral Vascular Devices Market, by End-User
- 13.1. Ambulatory Surgical Centers
- 13.2. Clinics
- 13.3. Hospitals
- 14. Peripheral Vascular Devices Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Peripheral Vascular Devices Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Peripheral Vascular Devices Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories
- 17.3.2. AngioDynamics, Inc.
- 17.3.3. Argon Medical Devices, Inc.
- 17.3.4. ASAHI INTECC CO., LTD
- 17.3.5. B. Braun SE
- 17.3.6. Baxter International Inc.
- 17.3.7. Becton, Dickinson and Company
- 17.3.8. BIOTRONIK SE & Co. KG
- 17.3.9. Boston Scientific Corporation
- 17.3.10. Cardinal Health, Inc.
- 17.3.11. Cook Group Incorporated
- 17.3.12. Esaote S.p.A.
- 17.3.13. FUJIFILM Holdings Corporation
- 17.3.14. GE HealthCare
- 17.3.15. Kimal PLC
- 17.3.16. Koninklijke Philips N.V.
- 17.3.17. Lepu Medical Technology (Beijing) Co., Ltd.
- 17.3.18. Medtronic PLC
- 17.3.19. Merit Medical Systems, Inc.
- 17.3.20. Nipro Corporation
- 17.3.21. Penumbra, Inc.
- 17.3.22. Sahajanand Medical Technologies Limited
- 17.3.23. Shockwave Medical, Inc. by Johnson & Johnson Services, Inc.
- 17.3.24. Siemens Healthineers AG
- 17.3.25. Summa Therapeutics, LLC
- 17.3.26. Teleflex Incorporated
- 17.3.27. Terumo Corporation
- 17.3.28. W. L. Gore & Associates, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
